Table 2.
Multiple logistic regression analysis regarding the effect of comedication on adverse events emerging during tamsulosin treatment.
| Iindependent variable | n | Odds ratio (95% CI) | P value |
|---|---|---|---|
| Age (per year) | 1784 | 1.003 (0.991, 1.016) | 678 |
| α-adrenoceptor blockers | 14 | 3.872 (1.523, 9.847) | 17 |
| Verapamil | 27 | 3.166 (1.513, 6.580) | 10 |
| Other Ca2+ antagonists | 99 | 1.632 (1.010, 2.639) | 93 |
| Nitrates | 76 | 1.840 (1.024, 3.309) | 87 |
| Converting enzyme inhibitors | 87 | 0.554 (0.290, 1.055) | 132 |
| β-adrenoceptor blockers | 88 | 1.056 (0.620, 1.797) | 867 |
| Diuretics | 55 | 0.773 (0.368, 1.623) | 568 |
| Oral antidiabetics | 66 | 1.072 (0.555, 2.070) | 863 |
| Insulin | 13 | 1.192 (0.286, 4.969) | 840 |
| Antilipaemics | 43 | 0.841 (0.372, 1.903) | 727 |
Note that odds ratios with 95% CI were calculated for each comedication separately while the P-values were calculated from the overall analysis including all comedications; hence, confidence not including unity for nitrates and ‘other Ca2+ antagonists’ do not correspond to statistical significance at the P < 0.05 level.